Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Capsules
Patent
1986-11-12
1989-05-02
Rose, Shep K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Capsules
424461, 424462, 424468, 424469, 424470, A61K 922, A61K 952
Patent
active
048266884
ABSTRACT:
A controlled absorption quinidine formulation for oral administration comprises a pellet having a core of quinidine or a pharmaceutically acceptable salt thereof in association with an organic acid and optionally other excipients, and an outer membrane which permits release of quinidine in an aqueous medium at a controlled rate which is substantially pH independent. The pellet has a dissolution rate in vitro, which when measured in a Basket Assembly according to U.S. Pharmacopoeia XXI at 37.degree. C. and 75 r.p.m. is not more than 15% after one hour of measurement. Not more than 50% of the total quinidine is release after a total of 4 hours of measurement, not more than 80% is released after a total of 8 hours of measurement and not less than 90% release is achieved after a total of 24 hours.
REFERENCES:
patent: 4341759 (1982-07-01), Bogentoft et al.
patent: 4361546 (1982-11-01), Stricker et al.
patent: 4432965 (1984-02-01), Keith et al.
patent: 4443428 (1984-04-01), Oshlaek et al.
patent: 4459279 (1984-07-01), Stricker et al.
patent: 4521401 (1985-06-01), Dunn
patent: 4572833 (1986-02-01), Pedersen et al.
patent: 4578264 (1986-03-01), Stricker et al.
patent: 4606909 (1986-08-01), Beatgaard et al.
patent: 4713248 (1987-12-01), Kjornaes et al.
patent: 4716041 (1987-12-01), Kjornaes et al.
Geoghegan Edward J.
Panoz Donald E.
501 Elan Corporation PLC.
Rose Shep K.
LandOfFree
Controlled absorption pharmaceutical formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled absorption pharmaceutical formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled absorption pharmaceutical formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-584055